Literature DB >> 23582658

Identification of β-amyloid species in canine cerebrospinal fluid by mass spectrometry.

Leticia Sarasa1, José Antonio Allué, Pedro Pesini, Angela González-Martínez, Manuel Sarasa.   

Abstract

It is well known that several Aβ species, including Aβ40 and Aβ42, are present in cerebrospinal fluid (CSF). Experimental results suggest that these species could play a role in Alzheimer's disease and might also have diagnostic significance. In the present work, the canine CSF β-amyloid species profile has been identified by matrix-assisted laser desorption and ionization-time-of-flight/time of flight mass spectrometry (MALDI-TOF/TOF) analysis after immunoprecipitation with different Aβ-specific antibodies. The results show that species arising from combined β- and γ-secretase activities in humans, such as Aβ1-33, Aβ1-34, Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40, and Aβ1-42, are also present in dogs. Species arising from combined α- and β-secretase activities, as well as other Aβ-degrading enzymes, are also present in both human and canine CSF, with the exception of Aβ1-13, Aβ1-14, and Aβ1-18, which are not detected in dogs. A large number of species truncated at Glu-3 and Glu-11 have also been detected. To our knowledge, this work describes a most complete Aβ species profile from canine CSF. The similarities between the canine and human CSF Aβ profile reinforce the dog as a highly appropriate animal model for research in Alzheimer's disease.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23582658     DOI: 10.1016/j.neurobiolaging.2013.03.009

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  3 in total

1.  Pharmacokinetics and Pharmacodynamic Effect of a Blood-Brain Barrier-Crossing Fusion Protein Therapeutic for Alzheimer's Disease in Rat and Dog.

Authors:  Etienne Lessard; Kerry Rennie; Arsalan Haqqani; Binbing Ling; James Whitfield; Andrea Paradis; Joseph Araujo; Nathan Yoganathan; John Gillard; Danica Stanimirovic; Balu Chakravarthy
Journal:  Pharm Res       Date:  2022-06-15       Impact factor: 4.580

Review 2.  Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges.

Authors:  Paulina R Davis; Elizabeth Head
Journal:  Front Pharmacol       Date:  2014-03-21       Impact factor: 5.810

3.  Outstanding Phenotypic Differences in the Profile of Amyloid-β between Tg2576 and APPswe/PS1dE9 Transgenic Mouse Models of Alzheimer's Disease.

Authors:  José Antonio Allué; Leticia Sarasa; María Izco; Virginia Pérez-Grijalba; Noelia Fandos; María Pascual-Lucas; Samuel Ogueta; Pedro Pesini; Manuel Sarasa
Journal:  J Alzheimers Dis       Date:  2016-05-30       Impact factor: 4.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.